Lupin spurts as its subsidiary receives green signal for anti-AIDS generic drug

16 May 2012 Evaluate

Lupin is currently trading at Rs. 548.85, up by 11.25 points or 2.09% from its previous closing of Rs. 537.60 on the BSE.

The scrip opened at Rs. 534.40 and has touched a high and low of Rs. 553.65 and Rs. 534.40 respectively. So far 20487 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 574.05 on 17-Apr-2012 and a 52 week low of Rs. 409.50 on 14-Dec-2011.

Last one week high and low of the scrip stood at Rs. 553.65 and Rs. 507.70 respectively. The current market cap of the company is Rs. 23991.81 crore.

The promoters holding in the company stood at 46.93% while Institutions and Non-Institutions held 44.05% and 9.02% respectively.

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Lamivudine and Zidovudine Tablets, 150 mg/300 mg from the United States Food and Drugs Administration (FDA). Lupin has already commenced shipping the product.

Lupin’s Lamivudine and Zidovudine Tablets are the AB rated generic equivalent of Viiv Healthcare’s Combivir  Tablets, 150/300 mg. Combivir Tablets, had annual US sales of approximately $27.5 crore for the twelve months ending December 2011 (IMS Health Sales Data).

Lamivudine Zidovudine is a combination of two nucleoside analogue reverse transcriplase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Lupin Share Price

2099.55 -13.40 (-0.63%)
29-Dec-2025 10:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.05
Dr. Reddys Lab 1265.10
Cipla 1502.20
Zydus Lifesciences 905.55
Lupin 2099.55
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×